Research programme: hydroxysteroid dehydrogenase inhibitors - Roche/Takeda San Diego
Alternative Names: 11β-HSD inhibitors; 11β-hydroxysteroid dehyderogenase inhibitorsLatest Information Update: 16 Jul 2016
At a glance
- Originator Roche; Takeda San Diego
- Class
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Switzerland
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 01 Mar 2005 Syrrx has been acquired by Takeda